A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Could targeting a enzyme play a role in slowing lung fibrosis? Boehringer Ingelheim’s research into PDE4B is offering ...
UNAGI, a deep generative neural network, tracks IPF progression and identifies potential therapies by analyzing cell types and disease-related genes. The model autonomously learns and refines itself, ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...
Pirfenidone is associated with fewer arrhythmic events and reduced diastolic dysfunction in patients with idiopathic pulmonary fibrosis.
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Dec. 22, 2025 /PRNewswire/ -- The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...
Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This article is more than 6 years old. Idiopathic pulmonary ...
A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results